Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Therapeutic Landscape | 11 | 16 |
| Heart Failure | 11 | 1 |
| Symptoms | 11 | 1 |
| Etiology | 12 | 1 |
| Pathophysiology | 12 | 1 |
| Co-morbidities and Complications | 12 | 1 |
| Diagnosis | 13 | 1 |
| Classification | 14 | 1 |
| Prognosis and Disease Staging | 14 | 1 |
| Treatment Options | 15 | 1 |
| Angiotensin-Converting Enzyme Inhibitors | 15 | 1 |
| Angiotensin II Receptor Blockers | 15 | 1 |
| Beta Blockers | 15 | 1 |
| Digoxin | 16 | 1 |
| Diuretics | 16 | 1 |
| Aldosterone Antagonists | 16 | 1 |
| Hydralazine and Nitrates | 16 | 1 |
| Treatment Algorithms and Prescribing Habits | 16 | 2 |
| Myocardial Infarction | 18 | 1 |
| Symptoms | 18 | 1 |
| Etiology | 18 | 1 |
| Pathophysiology | 18 | 1 |
| Co-morbidities and Complications | 19 | 1 |
| Diagnosis | 19 | 1 |
| Classification | 20 | 1 |
| Treatment Options | 21 | 1 |
| Antiplatelet Agents | 21 | 1 |
| Nitrates | 21 | 1 |
| Pain Control | 21 | 1 |
| Beta Blockers | 21 | 1 |
| Unfractionated Heparin | 21 | 1 |
| ACEIs and ARBs | 21 | 1 |
| Glycoprotein IIb/IIIa Antagonists | 21 | 1 |
| Statin Therapy | 21 | 1 |
| Other treatment options | 22 | 1 |
| Acute Coronary Syndrome | 22 | 1 |
| Symptoms | 22 | 1 |
| Etiology | 22 | 1 |
| Pathophysiology | 23 | 1 |
| Diagnosis | 23 | 1 |
| Treatment Options | 24 | 1 |
| Aspirin | 24 | 1 |
| Thrombolytics | 24 | 1 |
| Nitroglycerin | 24 | 1 |
| Beta blockers | 24 | 1 |
| ACEIs and ARBs | 24 | 1 |
| Calcium channel blockers | 25 | 1 |
| Cholesterol-lowering drugs | 25 | 1 |
| Clot-preventing drugs | 25 | 1 |
| Surgery and other procedures | 25 | 1 |
| Treatment Algorithm | 26 | 1 |
| Marketed Products | 27 | 12 |
| Heart Failure | 27 | 1 |
| Myocardial Infarction | 27 | 1 |
| Acute Coronary Syndrome | 27 | 1 |
| Key Marketed Products | 27 | 1 |
| Arixtra | 27 | 2 |
| Brilinta | 29 | 1 |
| Crestor | 30 | 1 |
| Diovan and Diovan HCT/Co-Diovan | 31 | 1 |
| Atacand | 31 | 1 |
| Lipitor | 32 | 1 |
| Clopidogrel bisulfate | 33 | 1 |
| Angiomax | 33 | 1 |
| Lovenox | 34 | 1 |
| Norvasc | 35 | 1 |
| Coreg | 35 | 2 |
| Ivabradine | 37 | 1 |
| Toprol-XL | 37 | 2 |
| Pipeline Analysis | 39 | 13 |
| Heart Failure Pipeline | 39 | 1 |
| Overall Pipeline | 39 | 1 |
| Pipeline Analysis by Molecule Type | 40 | 1 |
| Pipeline Analysis by Mechanism of Action | 41 | 1 |
| Myocardial Infarction Pipeline | 42 | 1 |
| Overall Pipeline | 42 | 1 |
| Pipeline Analysis by Molecule Type | 43 | 1 |
| Pipeline Analysis by Mechanism of Action | 44 | 1 |
| Acute Coronary Syndrome Pipeline | 45 | 1 |
| Overall Pipeline | 45 | 1 |
| Pipeline Analysis by Molecule Type | 46 | 1 |
| Pipeline Analysis by Mechanism of Action | 47 | 1 |
| Promising Drug Candidates in the Pipeline | 48 | 1 |
| LCZ-696 | 48 | 1 |
| Overview | 48 | 1 |
| Efficacy | 48 | 1 |
| Safety | 48 | 1 |
| Darapladib (SB-480848) | 49 | 1 |
| Overview | 49 | 1 |
| Efficacy | 49 | 1 |
| Safety | 49 | 1 |
| Neucardin | 50 | 1 |
| Overview | 50 | 1 |
| Efficacy | 50 | 1 |
| Safety | 50 | 1 |
| Cangrelor | 51 | 1 |
| Overview | 51 | 1 |
| Efficacy | 51 | 1 |
| Safety | 51 | 1 |
| Serelaxin (Novartis AG) | 51 | 1 |
| Cardiovascular Diseases Global Market to 2019, Market Forecast | 52 | 19 |
| Global Market | 52 | 1 |
| Treatment Usage Patterns | 52 | 1 |
| Annual Cost of Treatment | 52 | 1 |
| Market Size | 52 | 2 |
| US | 54 | 1 |
| Treatment Usage Patterns | 54 | 1 |
| Annual Cost of Treatment | 54 | 1 |
| Market Size | 54 | 2 |
| France | 56 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Annual Cost of Treatment | 56 | 1 |
| Market Size | 56 | 2 |
| Spain | 58 | 1 |
| Treatment Usage Patterns | 58 | 1 |
| Annual Cost of Treatment | 58 | 1 |
| Market Size | 58 | 2 |
| Germany | 60 | 1 |
| Treatment Usage Patterns | 60 | 1 |
| Annual Cost of Treatment | 60 | 1 |
| Market Size | 60 | 2 |
| Italy | 62 | 1 |
| Treatment Usage Patterns | 62 | 1 |
| Annual Cost of Treatment | 62 | 1 |
| Market Size | 62 | 2 |
| UK | 64 | 1 |
| Treatment Usage Patterns | 64 | 1 |
| Annual Cost of Treatment | 64 | 1 |
| Market Size | 64 | 2 |
| Japan | 66 | 1 |
| Treatment Usage Patterns | 66 | 1 |
| Annual Cost of Therapy | 66 | 1 |
| Market Size | 66 | 2 |
| Canada | 68 | 1 |
| Treatment Usage Patterns | 68 | 1 |
| Annual Cost of Treatment | 68 | 1 |
| Market Size | 68 | 2 |
| Drivers and Barriers for the Global Cardiovascular Diseases Market | 70 | 1 |
| Drivers | 70 | 1 |
| Fast-Track Product Registration Processes | 70 | 1 |
| Increasing Elderly Population | 70 | 1 |
| Healthcare Infrastructure | 70 | 1 |
| Barriers | 70 | 1 |
| Market Saturation due to Generic Drugs | 70 | 1 |
| High Cost of Newer Therapies | 70 | 1 |
| Deals and Strategic Consolidations | 71 | 9 |
| Deals Analysis | 71 | 2 |
| Major Co-development Deals | 73 | 1 |
| Genzyme Enters into Agreement with Osiris Therapeutics | 74 | 1 |
| Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics | 74 | 1 |
| Cytokinetics Signs Strategic Agreement with Amgen | 74 | 1 |
| Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. | 74 | 1 |
| Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. | 75 | 1 |
| Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited | 75 | 1 |
| Major Licensing Deals | 76 | 1 |
| Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine | 77 | 1 |
| The Medicines Company Enters into Licensing Agreement with Pfizer Inc. | 77 | 1 |
| BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. | 77 | 1 |
| KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb | 77 | 1 |
| Theravance, Inc. Enters into Licensing Agreement with Merck &Co., Inc. for Cardiovascular Therapeutic Candidates | 78 | 1 |
| Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. | 79 | 1 |
| Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck &Co, Inc. | 79 | 1 |
| Amgen Enters into Licensing Agreement with Cytokinetics | 79 | 1 |
| Appendix | 80 | 27 |
| Market Definitions | 80 | 1 |
| Abbreviations | 80 | 2 |
| Sources | 82 | 2 |
| All Pipeline Drugs by Phase | 84 | 10 |
| Preclinical | 84 | 3 |
| Pre-registration | 87 | 1 |
| Phase I | 88 | 1 |
| Phase II | 89 | 2 |
| Phase III | 91 | 1 |
| Discontinued | 92 | 1 |
| Filing rejected/Withdrawn | 93 | 1 |
| Market Forecasts to 2019 | 93 | 10 |
| Global | 93 | 1 |
| Heart Failure | 93 | 1 |
| Myocardial infarction | 93 | 1 |
| Acute Coronary Syndrome | 94 | 1 |
| US | 94 | 1 |
| Heart Failure | 94 | 1 |
| Myocardial Infarction | 94 | 1 |
| Acute Coronary Syndrome | 95 | 1 |
| UK | 95 | 1 |
| Heart Failure | 95 | 1 |
| Myocardial Infarction | 95 | 1 |
| Acute Coronary Syndrome | 96 | 1 |
| France | 96 | 1 |
| Heart Failure | 96 | 1 |
| Myocardial Infarction | 96 | 1 |
| Acute Coronary Syndrome | 97 | 1 |
| Spain | 97 | 1 |
| Heart Failure | 97 | 1 |
| Myocardial Infarction | 97 | 1 |
| Acute Coronary Syndrome | 98 | 1 |
| Germany | 98 | 1 |
| Heart Failure | 98 | 1 |
| Myocardial Infarction | 98 | 1 |
| Acute Coronary Syndrome | 99 | 1 |
| Italy | 99 | 1 |
| Heart Failure | 99 | 1 |
| Myocardial Infarction | 99 | 1 |
| Acute Coronary Syndrome | 100 | 1 |
| Japan | 100 | 1 |
| Heart Failure | 100 | 1 |
| Myocardial Infarction | 100 | 1 |
| Acute Coronary Syndrome | 101 | 1 |
| Canada | 101 | 1 |
| Heart Failure | 101 | 1 |
| Myocardial Infarction | 101 | 1 |
| Acute Coronary Syndrome | 102 | 1 |
| Research Methodology | 102 | 5 |
| Coverage | 102 | 1 |
| Secondary Research | 102 | 1 |
| Primary Research | 103 | 1 |
| Therapeutic Landscape | 103 | 1 |
| Epidemiology-Based Forecasting | 103 | 2 |
| Market Size by Geography | 105 | 1 |
| Geographical Landscape | 106 | 1 |
| Pipeline Analysis | 106 | 1 |
| Expert Panel Validation | 106 | 1 |
| Contact Us | 106 | 1 |
| Disclaimer | 106 | 1 |
